Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 425-435

  Matoulková, Petra ^a   Pávek, Petr ^a   Malý, Josef ^a   Vlček, Jiří ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Cytochrome P450 enzyme system; Drug interactions, information systems; Glucocorticoid receptors

Indexed keywords

CYTOCHROME P450; DEXAMETHASONE; GLUCOCORTICOID; XENOBIOTIC AGENT;

ANIMAL; DISEASE MODEL; DRUG INTERACTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; UPREGULATION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HUMANS; UP-REGULATION; XENOBIOTICS;

EID: 84894167162     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.878703     Document Type: Review

References (72)

1. Becker DE. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog 2013;60:25-31.quiz 32
2. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: Antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002;71:9-15
3. Teuffel O, Kuster SP, Hunger SP, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: A systematic review and meta-analysis. Leukemia 2011;25:1232-8
4. Vaidya JS, Baldassarre G, Thorat MA, Massarut S. Role of glucocorticoids in breast cancer. Curr Pharm Des 2010;16:3593-600
5. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004;9:571-91
6. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010;49:239-48
7. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007;32:169-75
8. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003;56:327-30
9. Hromadkova L, Soukup T, Vlcek J. Important drug interactions in patients with rheumatic disorders: Interactions of glucocorticoids, immunosuppressants and antimalarial drugs. Drugs Today (Barc) 2012;48:545-53
10. Dvorak Z, Pavek P. Regulation of drugmetabolizing cytochrome p450 enzymes by glucocorticoids. Drug Metab Rev 2010;42:621-35. Comprehenive review of molecular mechanisms of CYP induction by glucocorticoids.
11. David nelson's p450 homepage. Available from: Http://drnelson.Utmem.Edu/ human.P450.Table.Html. An electoric database of CYP enzymes.
12. Anzenbacher P, Anzenbacherova E. Cytochromes p450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47. Excellent review of cytochrome P450 enzymes.
13. Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: A family affair. Trends Endocrinol Metab 2008;19:331-9. Excellent review on GC.
14. Revollo JR, Cidlowski JA. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 2009;1179:167-78. Excellent review on GCs.
15. Reichardt HM, Kaestner KH, Wessely O, et al. Analysis of glucocorticoid signalling by gene targeting. J Steroid Biochem Mol Biol 1998;65:111-15
16. Zilliacus J, Wright AP, Carlstedt-Duke J, Gustafsson JA. Structural determinants of DNA-binding specificity by steroid receptors. Mol Endocrinol 1995;9:389-400
17. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001;79:376-84 . Review on anti-inflammatory effects of GC.
18. Schuetz JD, Schuetz EG, Thottassery JV, et al. Identification of a novel dexamethasone responsive enhancer in the human cyp3a5 gene and its activation in human and rat liver cells. Mol Pharmacol 1996;49:63-72
19. Gerbal-Chaloin S, Daujat M, Pascussi JM, et al. Transcriptional regulation of cyp2c9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 2002;277:209-17
20. Pavek P, Cerveny L, Svecova L, et al. Examination of glucocorticoid receptor alpha-mediated transcriptional regulation of p-glycoprotein, cyp3a4, and cyp2c9 genes in placental trophoblast cell lines. Placenta 2007;28:1004-11
21. Chen Y, Goldstein JA. The transcriptional regulation of the human cyp2c genes. Curr Drug Metab 2009;10:567-78
22. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the cyp2c19 promoter. Mol Pharmacol 2003;64:316-24
23. Ferguson SS, Chen Y, LeCluyse EL, et al. Human cyp2c8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane x receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005;68:747-57
24. Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane x receptor (hpxr) and correlation to known cyp3a4 drug interactions. Curr Drug Metab 2006;7:375-88 . A paper that show interaction of commonly used drugs with PXR.
25. Onica T, Nichols K, Larin M, et al. Dexamethasone-mediated up-regulation of human cyp2a6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4{alpha} to the proximal promoter. Mol Pharmacol 2008;73:451-60
26. Barwick JL, Quattrochi LC, Mills AS, et al. Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human cyp3a4 and rabbit cyp3a6 in primary cultures of adult rat and rabbit hepatocytes. Mol Pharmacol 1996;50:10-16
27. Ogg MS, Williams JM, Tarbit M, et al. A reporter gene assay to assess the molecular mechanisms of xenobioticdependent induction of the human cyp3a4 gene in vitro. Xenobiotica 1999;29:269-79
28. El-Sankary W, Plant NJ, Gibson GG, Moore DJ. Regulation of the cyp3a4 gene by hydrocortisone and xenobiotics: Role of the glucocorticoid and pregnane x receptors. Drug Metab Dispos 2000;28:493-6
29. El-Sankary W, Bombail V, Gibson GG, Plant N. Glucocorticoid-mediated induction of cyp3a4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane x receptor response element. Drug Metab Dispos 2002;30:1029-34
30. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome p450 superfamily in human extrahepatic tissues. Curr Drug Metab 2008;9:129-43 . A review on extrahepatic regulation of CYPs.
31. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of cyp2b6, cyp2c9 and cyp3a4 genes: A tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-53
32. Martinez-Jimenez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of cyp3a4 in hepatocytes. Curr Drug Metab 2007;8:185-94
33. Pascussi JM, Drocourt L, Fabre JM, et al. Dexamethasone induces pregnane x receptor and retinoid x receptor-alpha expression in human hepatocytes: Synergistic increase of cyp3a4 induction by pregnane x receptor activators. Mol Pharmacol 2000;58:361-72
34. Pascussi JM, Drocourt L, Gerbal-Chaloin S, et al. Dual effect of dexamethasone on cyp3a4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane x receptor. Eur J Biochem 2001;268:6346-58
35. Pascussi JM, Gerbal-Chaloin S, Fabre JM, et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome p450 gene regulation. Mol Pharmacol 2000;58:1441-50
36. Harper PA, Riddick DS, Okey AB. Regulating the regulator: Factors that control levels and activity of the aryl hydrocarbon receptor. Biochem Pharmacol 2006;72:267-79
37. Linder MW, Falkner KC, Srinivasan G, et al. Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. Drug Metab Rev 1999;31:247-71
38. Monostory K, Pascussi JM, Kobori L, Dvorak Z. Hormonal regulation of cyp1a expression. Drug Metab Rev 2009;41:547-72
39. Vrzal R, Stejskalova L, Monostory K, et al. Dexamethasone controls aryl hydrocarbon receptor (ahr)-mediated cyp1a1 and cyp1a2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact 2009;179:288-96
40. Kosir R, Spaninger K, Rozman D. Circadian events in human diseases and in cytochrome p450-related drug metabolism and therapy. IUBMB Life 2013;65:487-96
41. Lu YF, Jin T, Xu Y, et al. Sex differences in the circadian variation of cytochrome p450 genes and corresponding nuclear receptors in mouse liver. Chronobiol Int 2013;30:1135-43
42. Li AP, Maurel P, Gomez-Lechon MJ, et al. Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary human hepatocytes in the evaluation of cytochrome p450 induction. Chem Biol Interact 1997;107:5-16
43. Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 2008;4:837-54
44. Wadhwa NK, Schroeder TJ, Pesce AJ, et al. Cyclosporine drug interactions: A review. Ther Drug Monit 1987;9:399-406
45. Backman L, Kreis H, Morales JM, et al. Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br J Clin Pharmacol 2002;54:65-8
46. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to cyp3a5 and mdr1 polymorphisms and steroids. Transplantation 2005;80:977-84
47. van Duijnhoven EM, Boots JM, Christiaans MH, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003;16:721-5
48. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003;18:2409-14
49. Kuypers DR, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004;43:741-62
50. Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction? Ann Pharmacother 2008;42:1037-47
51. Teo YL, Saetaew M, Chanthawong S, et al. Effect of cyp3a4 inducer dexamethasone on hepatotoxicity of lapatinib: Clinical and in vitro evidence. Breast Cancer Res Treat 2012;133:703-11 . A clinical and in vitro evidence on DDI between lapatinib and dexamethasone.
52. Ranson M, Reck M, Anthoney A, et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (nsclc): A phase I dose-finding study. Ann Oncol 2010;21:2233-9
53. Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004;103:67-72
54. Urien S, Doz F, Giraud C, et al. Developmental pharmacokinetics of etoposide in 67 children: Lack of dexamethasone effect. Cancer Chemother Pharmacol 2011;67:597-603
55. Hellmann A, Rule S, Walewski J, et al. Effect of cytochrome p450 3a4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-hodgkin's lymphoma. Clin Pharmacokinet 2011;50:781-91
56. Bruggemann SK, Pfaffle S, Peters SO, Wagner T. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Drug Metab Dispos 2007;35:1721-4
57. Moore MJ, Hardy RW, Thiessen JJ, et al. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988;44:622-8
58. Loos WJ, de Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12
59. Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 1987;37:1561-2
60. Song IH, Borland J, Chen S, et al. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2013;57:4394-7
61. Nakajima M, Suzuki T, Sasaki T, et al. Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. Ther Drug Monit 1999;21:507-13
62. Villikka K, Varis T, Backman JT, et al. Effect of methylprednisolone on cyp3a4-mediated drug metabolism in vivo. Eur J Clin Pharmacol 2001;57:457-60
63. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Potentiation of vitamin k antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 2000;132:631-5 . Evidence on INR rise after concomitantly administered pulse high-dose intravenous methylprednisolone and oral anticoagulants. Possible mechanism - inhibition of CYP450 dependent catabolism of oral anticoagulants.
64. Sellam J, Costedoat-Chalumeau N, Amoura Z, et al. Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and al amyloidosis. Joint Bone Spine 2007;74:446-52
65. Henricsson S, Lindholm A, Aravoglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol 1990;66:49-52
66. Lin JH. Cyp induction-mediated drug interactions: In vitro assessment and clinical implications. Pharm Res 2006;23:1089-116 . Good review on DDIs based on CYP induction.
67. Blumberg B, Sabbagh W Jr, Juguilon H, et al. Sxr, a novel steroid and xenobioticsensing nuclear receptor. Genes Dev 1998;12:3195-205
68. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98
69. Needs CJ, Smith M, Boutagy J, et al. Comparison of methylprednisolone (1 g i.V.) with prednisolone (1 g orally) in rheumatoid arthritis: A pharmacokinetic and clinical study. J Rheumatol 1988;15:224-8
70. Narang PK, Wilder R, Chatterji DC, et al. Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. Biopharm Drug Dispos 1983;4:233-48
71. Novotna A, Pavek P, Dvorak Z. Construction and characterization of a reporter gene cell line for assessment of human glucocorticoid receptor activation. Eur J Pharm Sci 2012;47:842-7
72. DRUGDEX System [Internet database]. Greenwood Village CTHUp